Opthea (ASX:OPT) Equity-to-Asset : -0.28 (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Opthea Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Opthea's Total Stockholders Equity for the quarter that ended in Dec. 2023 was A$-70.09 Mil. Opthea's Total Assets for the quarter that ended in Dec. 2023 was A$248.75 Mil. Therefore, Opthea's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.28.

The historical rank and industry rank for Opthea's Equity-to-Asset or its related term are showing as below:

ASX:OPT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28 Med: 0.87 Max: 0.98
Current: -0.28

During the past 13 years, the highest Equity to Asset Ratio of Opthea was 0.98. The lowest was -0.28. And the median was 0.87.

ASX:OPT's Equity-to-Asset is ranked worse than
87.47% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs ASX:OPT: -0.28

Opthea Equity-to-Asset Historical Data

The historical data trend for Opthea's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opthea Equity-to-Asset Chart

Opthea Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Equity-to-Asset

Get a 7-Day Free Trial

0.83

0.90

0.98

0.80

-0.06

Opthea Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.92	0.80	0.37	-0.06	-0.28

Competitive Comparison of Opthea's Equity-to-Asset

For the Biotechnology subindustry, Opthea's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Opthea's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opthea's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Opthea's Equity-to-Asset falls into.

Opthea Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Opthea's Equity to Asset Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Equity to Asset (A: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-8.721	/	146.975
	=	-0.06

Opthea's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-70.09	/	248.752
	=	-0.28

Opthea (ASX:OPT) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Opthea Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Opthea's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Opthea (ASX:OPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opthea Ltd (ASX:OPT) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

OPT:USA UKJ:Germany

Address

650 Chapel Street, Level 4, Suite 0403, South Yarra, VIC, AUS, 3141

Website

https://www.opthea.com

Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.